Alexander Zehnder is to join CureVac NV on 1 April as chief executive officer, succeeding Franz Haas. Dr Zehnder is currently global head of oncology at Sanofi SA. Before this, he led country management positions at the France-based multinational. Earlier, he was an executive at the Roche Group where he led global product strategy and managed the commercial development of Avastin, the cancer drug. Dr Zehnder received his medical degree from the University of Bern and completed a master of business administration degree at the IMD Business School in Lausanne, both in Switzerland.
CureVac announced the appointment on 9 January 2023.
Copyright 2023 Evernow Publishing Ltd